Deubiquitinases and the new therapeutic opportunities offered to cancer

    1. Vivian Saridakis
    1. Department of Biology, York University, 4700 Keele Street, Toronto, Ontario, Canada, M3J1P3
    1. Correspondence should be addressed to V Saridakis; Email: vsaridak{at}


    Deubiquitinases (DUBs) play important roles and therefore are potential drug targets in various diseases including cancer and neurodegeneration. In this review, we recapitulate structure–function studies of the most studied DUBs including USP7, USP22, CYLD, UCHL1, BAP1, A20, as well as ataxin 3 and connect them to regulatory mechanisms and their growing protein interaction networks. We then describe DUBs that have been associated with endocrine carcinogenesis with a focus on prostate, ovarian, and thyroid cancer, pheochromocytoma, and adrenocortical carcinoma. The goal is enhancing our understanding of the connection between dysregulated DUBs and cancer to permit the design of therapeutics and to establish biomarkers that could be used in diagnosis and prognosis.

    • Revision received 22 December 2014
    • Accepted 23 December 2014
    | Table of Contents